期刊
MAYO CLINIC PROCEEDINGS
卷 87, 期 7, 页码 659-673出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2012.03.011
关键词
-
资金
- Arthritis Foundation, Indianapolis, IN
- Centocor
- Genentech
- Mayo Foundation, Rochester, MN
- Myriad RBM, Inc, Austin, TX
- National Center for Research Resources and National Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
- Novartis Corp
- UCB Pharma, Inc
- University of Nebraska Medical Center Cooperative Studies Program
- Amgen, Bristol-Myers Squibb, New York, NY
- Centocor/Johnson Johnson
- Novartis
- National Institutes of Health, Bethesda, MD
- Veteran's Administration, US Department of Veterans Affairs, Washington, DC
The past decade has brought important advances in the understanding of rheumatoid arthritis and its management and treatment. New classification criteria for rheumatoid arthritis, better definitions of treatment outcome and remission, and the introduction of biologic response-modifying drugs designed to inhibit the inflammatory process have greatly altered the approach to managing this disease. More aggressive management of rheumatoid arthritis early after diagnosis and throughout the course of the disease has resulted in improvement in patient functioning and quality of life, reduction in comorbid conditions, and enhanced survival. (C) 2012 Mayo Foundation for Medical Education and Research Mayo Clin Proc. 2012;87(7);659-673
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据